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Disorder
Abstract
BACKGROUND: We investigated whether performance on a reward processing task differs between
fully remitted patients with major depressive disorder (MDD) and healthy control subjects after
catecholamine depletion. METHODS: Seventeen unmedicated subjects with remitted MDD (RMDD)
and 13 healthy control subjects underwent catecholamine depletion with oral alpha-methyl-para-tyrosine
(AMPT) in a randomized, placebo-controlled, double-blind crossover study. The main outcome measure
was the reaction time on the monetary incentive delay (MID) task. RESULTS: A diagnosis x drug
interaction was evident (p = .001), which was attributable to an increase in reaction time across all
incentive levels after AMPT in RMDD subjects (p = .001) but no significant AMPT effect on reaction
time in control subjects (p = .17). There was no drug x diagnosis interaction on control tasks involving
working memory or attention. In the RMDD sample the AMPT-induced depressive symptoms
correlated with AMPT-induced changes in reaction time at all incentive levels of the MID task (r values
= .58-.82, p < .002). CONCLUSIONS: Under catecholamine depletion the RMDD subjects were
robustly differentiated from control subjects by development of performance deficits on a reward
processing task. These performance deficits correlated directly with the return of depressive symptoms
after AMPT administration. The sensitivity of central reward processing systems to reductions in brain
catecholamine levels thus seems to represent a trait-like marker in MDD.
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onathan Roiser, Brian Knutson, Dennis S. Charney, and Wayne C. Drevets
ackground: We investigated whether performance on a reward processing task differs between fully remitted patients with major
epressive disorder (MDD) and healthy control subjects after catecholamine depletion.
ethods: Seventeen unmedicated subjects with remitted MDD (RMDD) and 13 healthy control subjects underwent catecholamine
epletion with oral -methyl-para-tyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study. The main outcome
easure was the reaction time on the monetary incentive delay (MID) task.
esults: A diagnosis drug interaction was evident (p .001), which was attributable to an increase in reaction time across all incentive
evels after AMPT in RMDD subjects (p .001) but no significant AMPT effect on reaction time in control subjects (p .17). There was no
rug diagnosis interaction on control tasks involving working memory or attention. In the RMDD sample the AMPT-induced depressive
ymptoms correlated with AMPT-induced changes in reaction time at all incentive levels of the MID task (r values .58–.82, p .002).
onclusions: Under catecholamine depletion the RMDD subjects were robustly differentiated from control subjects by development of
erformance deficits on a reward processing task. These performance deficits correlated directly with the return of depressive symptoms
fter AMPT administration. The sensitivity of central reward processing systems to reductions in brain catecholamine levels thus seems to
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mpaired function in the processing of reward-related stimuli
might constitute a key behavioral endophenotype in major
depressive disorder (MDD) (1–6). This behavioral deficit
ossibly reflects the biological endophenotype of reduced me-
olimbic dopaminergic function in depression (7). A tool that
otentially facilitates investigations of the relationship between
entral dopaminergic function and impairments in reward pro-
essing in depression is the monetary incentive delay (MID) task
f Knutson et al. (8). This task assesses appetitive and effort-
elated aspects of central reward processing in humans.
An instructive paradigm for investigating the relationship
etween catecholaminergic function and behavior has involved
he mood response to catecholamine depletion (CD), achieved
y oral administration of -methyl-paratyrosine (AMPT) (1,9), a
ompetitive inhibitor of tyrosine hydroxylase (10). The AMPT
hallenge studies in depression have not involved neuropsycho-
ogical testing that assesses core depressive features.
The main goal of the current study was to evaluate differential
esponses of the brain reward system to catecholamine depletion
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oi:10.1016/j.biopsych.2009.02.029in remitted patients with MDD and healthy control subjects with
the MID task (8). The specificity of catecholamine depletion
effects on reward processing was assessed by measuring AMPT-
induced changes in other cognitive domains with the N-back task
(working memory) and the Attention Network Test (ANT) (at-
tention).
Methods andMaterials
Participants
Individuals (18–56 years) either met DSM-IV criteria for MDD
in full remission (RMDD) or had no history of any psychiatric
disorder and no major psychiatric condition in first-degree
relatives. Recruitment strategy, screening methods, and inclusion
and exclusion criteria are described in (7). Written informed
consent was obtained as approved by the National Institute of
Mental Health Institutional Review Board. Data from the same
subjects on neural responses to AMPT were published in (7).
Experimental Design
With a randomized, double-blind, placebo-controlled cross-
over design, subjects underwent two identical sessions separated
by at least 1 week, in which they received either a body-weight
adjusted AMPT dose or placebo (as detailed in [7]). Behavioral
ratings obtained are listed in Figures 1 and 2; the scoring of the
educational level is described in Supplement 1.
Neuropsychological Testing
The neuropsychological assessment started 32 hours after
initiating AMPT administration and included measures of
working memory (N-back task), attention (ANT), and reward
processing (MID). In each session subjects were trained in
each task on the day before the neuropsychological testing,
and they performed a practice run immediately before testing
in each session. The task order in each session was: MID,
N-back, ANT. In the N-back and ANT tasks, there was no
BIOL PSYCHIATRY 2009;xx:xxx
© 2009 Society of Biological Psychiatry.
Published by Elsevier Inc. All rights reserved.
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ARTICLE IN PRESSeedback to show that subjects performed correctly or incor-
ectly. The neuropsychological tests and statistical analyses
re described in Supplement 1.
esults
Subject sample characteristics are detailed in (7). The educa-
ional level achieved did not differ significantly between groups
mean in RMDD subjects  6.2  .95, and mean in control
ubjects 6.3 .63; p .67). The neuropsychological data were
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igure 1. Behavioral response to catecholamine depletion and placebo in un-
edicated, remitted subjectswithmajor depressive disorder (RMDD) andhealthy
ubjects (control). AMPT, -methyl-para-tyrosine; MADRS, Montgomery-Asberg
epressionRatingScale;BDI,BeckDepression Inventory;HAMD,HamiltonDepres-
ion Rating Scale; BAI, Beck Anxiety Inventory; SHAPS, Snaith–Hamilton Pleasure
cale; ADS, Akathisia Determination Scale; SSS, Stanford Sleepiness Scale. a Sig-
ificantdiagnosiseffect(rMDDvsControls,p .05);bsignificanttreatmenteffect
or rMDD; c significant treatmenteffect forControls.navailable for between one and four RMDD subjects (depend-
ww.sobp.org/journaling on the task), due to technical problems with the task
computer.
Clinical Ratings
Figure 1 shows the mean ratings of mood and anxiety
symptoms, sleepiness, and akathisia for each treatment condi-
tion and group. Figure 2 shows the course of hypomanic
symptoms classified by treatment and group. The statistical
analyses of the clinical ratings and the neuropsychological tests
are described in Supplement 1.
N-Back Task
The RMDD subjects and control subjects did not differ
significantly on either performance accuracy [F (1, 41.3)  .30,
p  .59] or reaction time [F (1, 35.0)  .47, p  .50]. In pairwise
comparisons the main effects of drug or diagnosis and the
diagnosis  drug  difficulty level interaction did not approach
significance on any of the four task-difficulty levels (for accuracy,
p values  .19; for reaction time, p values  .09) (Figure 3).
ANT
Figure 4 shows the effects of diagnosis and drug on perfor-
mance, as assessed by reaction time differences on correct
responses and differences in percent correct responses with
respect to alertness, orientation, and executive attention. Alert-
ness scores were lower under AMPT than under placebo, on the
basis of differences in reaction time [F (1, 26.3)  7.58, p  .01].
However, the drug  diagnosis interactions involving reaction
time or accuracy (% correct) did not approach significance (p 
.53). The attention orientation times (difference in reaction time
between trials with and without spatial cues) were lower in
RMDD subjects than in control subjects irrespective of treatment
condition [F (1, 49.7)  5.10, p  .03].
MID Task
Valid MID task data from both sessions were available for 13
of the 17 RMDD subjects and all 13 control subjects. Reaction
time data classified by diagnosis and drug are displayed in Figure 5.
Testing within-subjects effects, we found a significant diagnosis 
drug interaction [F(1, 17.3)  14.4, p  .001], which was attribut-
able to a significant increase in reaction time across all incentive
levels after AMPT in RMDD subjects (p .001), but no significant
AMPT effect on reaction time in control subjects (p .17). Higher
incentive levels were associated with shorter reaction times [F (6,
6.6)  8.77, p  .007].
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Figure 2. Hypomanic symptoms developing 48 hours after catecholamine
depletion and placebo in unmedicated, remitted subjects with major de-
pressive disorder (RMDD) and healthy subjects (control). AMPT, -methyl-
para-tyrosine; YMRS, Young Mania Rating Scale. a  Significant diagnosis
effect (rMDDvsControls,p .05), b significant treatment effect for rMDD.
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ARTICLE IN PRESSFigure 3. Working memory performance on the N-Back
task classified by diagnosis and treatment condition. The x
axis indicates the difficulty level (N). AMPT, -methyl-para-
tyrosine; rMDD, remitted major depressive disorder.igure 4. Reaction time and%correct responses in the attention network test classified by diagnosis and treatment condition. The y axes indicate differences
etween two conditions (e.g., with and without alerting cues) in terms of reaction time (msec) and the rate of correct response (%). AMPT, -methyl-para-
yrosine; rMDD, remitted major depressive disorder.
www.sobp.org/journal
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ARTICLE IN PRESSIn RMDD subjects, the AMPT-induced depressive symptoms,
ssessed with the intrasession change in Montgomery-Asberg
epression rating scale (MADRS) scores, correlated with the
MPT-induced changes in reaction time at all incentive levels (r
alues ranged from .58 to .82, p  .002) (Figure 6). Including
oth depressive (MADRS) and manic (Young Mania Rating Scale)
ymptoms in the regression analysis did not change the signifi-
ance of the association between MADRS scores and MID task
erformance.
The RMDD subjects earned $81.13 39.36 under placebo and
67.87  39.35 under AMPT. Control subjects earned $93.47 
9.36 under placebo and $89.07  39.36 under AMPT. Neither
rug [F (1, 25.4)  .68, p  .42] nor diagnosis [F (1, 25.4)  2.46,
 .13] had a significant effect on money earned, and the
rug  diagnosis interaction was not significant [F(1, 25.4)  .17,
 .68].
iscussion
This study showed that RMDD subjects but not healthy
ontrol subjects show slower reaction times while performing the
ID task under catecholamine depletion. Such diagnosis  drug
nteractions on reaction time were not significant for the other
ognitive tasks that did not involve rewarded cues, suggesting
hat under catecholamine depletion remitted subjects with a
istory of MDD manifest a relatively selective deficit on a task
hat involved modulation of performance by monetary reward.
he correlation between AMPT-induced changes in reaction
imes on the MID task and AMPT-induced depressive symptoms
uggest the findings hold clinical relevance.
This is the first study that examined specifically the role of
atecholamines in reward processing associated with primary
ood disorders. The modulation of reward-directed behavior
igure 5. Reaction time in themonetary incentive delay task classified by in
ncentive. Positive values refer to money that can be earned; negative value
ajor depressive disorder.n RMDD subjects via catecholamine depletion holds scientific
ww.sobp.org/journaland clinical relevance given evidence that reduced dopamine
neurotransmission might contribute to the anhedonia and loss
of behavioral incentive in MDD (2,11,12). Moreover, dopami-
nergic transmission might play a role in the nonhedonic
reward processing (13), because studies in experimental
animals suggest that dopamine is critically involved in behav-
ior activation, “wanting” and effortful behavior that possibly
relates to depressive symptoms such as psychomotor slowing,
anergia, and inertia (14). The current study extends the
preclinical evidence for catecholamines’ role in reward pro-
cessing (although not differentiating between the effects of
dopamine and norepinephrine), by showing that catechol-
amine depletion reduces the ability to experience pleasure (as
assessed with the Snaith–Hamilton Pleasure Scale [SHAPS])
and impairs performance on reward-directed tasks (as mea-
sured with the MID task) in susceptible individuals identified
by having a history of MDD. The observation that AMPT-
induced slowing in reaction time in the MID task did not
significantly correlate with AMPT-induced reductions in the
subjective ability to experience pleasure (SHAPS) suggests
that these two measures assessed distinct aspects of the
processing of rewarding stimuli.
The hypomanic rebound effect 48–96 hours after initiating
AMPT most clearly differentiated RMDD subjects from control
subjects. A similar rebound effect after AMPT was reported in
patients with lithium-induced, long-term remission of bipolar
disorder (15), but this effect was unexpected in remitted
subjects with MDD. Among the three subjects whose YMRS
score increased 7 points, one had a first-degree relative with
bipolar disorder, one had a second-degree relative with
bipolar disorder, and one had a second-degree relative with a
psychotic disorder (this was the only subject with a family
e level, diagnosis, and treatment condition. The x axis indicates the level of
r to money that can be lost. AMPT, -methyl-para-tyrosine; rMDD, remittedcentiv
s refehistory of psychosis).
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ARTICLE IN PRESSSeveral limitations of our study design merit comment. We
id not include an active placebo, because the pharmacolog-
cal actions of sedatives might have affected task performance.
evertheless, it is unlikely that nonspecific sedative effects of
MPT contributed to the diagnosis  drug interactions iden-
ified on the MID task, because the RMDD subjects and control
ubjects did not differ on the sedative effects of AMPT, and
erformance on the other neuropsychological tasks did not
iffer between RMDD subjects and control subjects. The
elatively small sample of subjects, missing data, a mostly
emale sample, and the ability of RMDD subjects to remain in
emission without current treatment reduced the generaliz-
bility of the results.
In summary, this study suggests that sensitivity of brain
eward systems to reductions in central catecholamine levels
epresents a trait-like biological marker in MDD (because
MDD subjects were assessed while unmedicated and remit-
ed). In addition, RMDD subjects were more sensitive than
ontrol subjects to developing mood changes during fluctua-
ions in catecholamine levels. Our experiment’s cross-sec-
ional design did not allow us to determine whether the
igure 6. Correlation between the AMPT-induced change in the monetary
ncentive delay (MID) task performance and the AMPT-induced depressive
ymptoms. The AMPT-induced changes in reaction time on the monetary
ncentive delay task (MID RT) correlated positively with the corresponding
hanges in depressive symptoms rated by the MADRS at 36 hours after
nitiating AMPT administration (r .64, p .0006). The change in RT values
or each subject reflects the difference in the average RT value across all
ncentive levels obtained under AMPT versus that obtained under placebo.
he difference between the MADRS score obtained for each subject in the
MPT session versus the placebo session was calculated to reflect themag-
itude of the AMPT-induced effect on depression ratings. Data from RMDD
ubjects are in blue; data from control subjects are in black. Other abbrevi-
tions as in Figure 1.epressive response to AMPT in RMDD subjects reflected anendophenotypic vulnerability to depression or a consequence
of past illness. Nevertheless, because the AMPT-induced neu-
ropsychological changes seem to constitute relatively specific
and persistent characteristics of MDD, this study encourages
further research to evaluate the neurobiological basis for
differential regulation or sensitivity to changes in catechol-
amine levels as an endophenotype in affective illness (1,16).
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